Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex

• Published in: Respiratory medicine case reports Vol. 34; p. 101526
• Main Authors: Shoji, Tetsuaki, Niida, Yo, Osawa, Takahiro, Matsumoto, Ryuji, Sakurai, Kotaro, Suzuki, Masaru, Matsuno, Yoshihiro, Konno, Satoshi
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.01.2021; Elsevier
• Subjects: Case Report; Everolimus; Multifocal micronodular pneumocyte hyperplasia; Surfactant Protein-A (SP-A); Surfactant protein-B (SP–B); Tuberous sclerosis complex; Surfactant Protein-A (SP-A); Surfactant protein-B (SP–B); Multifocal micronodular pneumocyte hyperplasia; Everolimus; Tuberous sclerosis complex
• ISSN: 2213-0071; 2213-0071
• DOI: 10.1016/j.rmcr.2021.101526

A woman with a diagnosis of tuberous sclerosis complex (TSC) presented with TSC2 gene mutation and various manifestations, including epilepsy, renal angiomyolipomas (AML), and pathologically confirmed multifocal micronodular pneumocyte hyperplasia (MMPH). With oral administration of everolimus, a mammalian target of rapamycin (mTOR) inhibitor, MMPH and AML were markedly reduced. Further, after starting treatment with everolimus, serum levels of surfactant protein (SP)-A and SP-D, which reflect type II pneumocyte hyperplasia, decreased to the normal range. At the time of writing of this manuscript, 6 years after starting everolimus, MMPH lesions did not relapse and SP-A/D remained the low levels. This is the first case of everolimus efficacy shown for histologically confirmed MMPH in genetically determined TSC patient, with time course of serum SP-A and SP-D.